Bio Rad Laboratories (BIO) Stock Price

Bio Rad Laboratories Price

NYSE·CLOSED
316.38USD+10.42 (+3.35 %)
Market closed

Revenue has compounded at 3.8% per year over the past 19 years to 2.58 B USD. Earnings per share have grown at 11.1% per year over the last 19 years. Bio Rad Laboratories's net margin stands at 29.4%, down from 145.6% several years earlier. Analysts set a median price target of 372.30 USD, implying 17.7% above the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 31% above its 52-week low.

Bio Rad Laboratories stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Bio Rad Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bio Rad Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bio Rad Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Bio Rad Laboratories Stock Price History
DateBio Rad Laboratories Price
7/23/2026316.38 USD
7/22/2026305.96 USD
7/21/2026301.70 USD
7/20/2026301.90 USD
7/17/2026304.36 USD
7/16/2026300.98 USD
7/15/2026295.73 USD
7/14/2026298.34 USD
7/13/2026298.26 USD
7/10/2026296.11 USD
7/9/2026297.28 USD
7/8/2026290.00 USD
7/7/2026292.50 USD
7/6/2026293.29 USD
7/2/2026296.86 USD
7/1/2026297.09 USD
6/30/2026293.61 USD
6/29/2026295.99 USD
6/26/2026300.79 USD
6/25/2026298.29 USD
6/24/2026280.05 USD
6/23/2026270.32 USD
6/22/2026277.88 USD
6/18/2026282.86 USD
6/17/2026289.82 USD
6/16/2026292.19 USD
6/15/2026287.62 USD
6/12/2026287.31 USD
6/11/2026290.30 USD
6/10/2026292.96 USD
6/9/2026297.17 USD
6/8/2026291.31 USD
6/5/2026297.88 USD
6/4/2026310.63 USD
6/3/2026303.79 USD
6/2/2026306.69 USD
6/1/2026309.83 USD
5/29/2026317.68 USD
5/28/2026317.98 USD
5/27/2026303.68 USD
5/26/2026290.13 USD
5/22/2026287.03 USD
5/21/2026288.46 USD
5/20/2026281.30 USD
5/19/2026281.05 USD
5/18/2026281.82 USD
5/15/2026247.53 USD
5/14/2026246.27 USD
5/13/2026243.51 USD
5/12/2026241.71 USD
5/11/2026243.79 USD
5/8/2026254.32 USD
5/7/2026257.32 USD
5/6/2026259.02 USD
5/5/2026257.12 USD
5/4/2026257.86 USD
5/1/2026256.55 USD
4/30/2026280.12 USD
4/29/2026275.15 USD
4/28/2026279.34 USD
4/27/2026287.29 USD
4/24/2026287.84 USD
4/23/2026281.42 USD
4/22/2026300.78 USD
4/21/2026305.67 USD
4/20/2026303.34 USD
4/17/2026299.02 USD
4/16/2026291.09 USD
4/15/2026295.96 USD
4/14/2026292.23 USD
4/13/2026288.17 USD
4/10/2026279.25 USD
4/9/2026277.50 USD
4/8/2026281.15 USD
4/7/2026278.00 USD
4/6/2026278.85 USD
4/2/2026279.99 USD
4/1/2026278.36 USD
3/31/2026278.75 USD
3/30/2026270.36 USD
3/27/2026265.40 USD
3/26/2026276.53 USD
3/25/2026273.60 USD
3/24/2026272.12 USD
3/23/2026265.00 USD
3/20/2026264.49 USD
3/19/2026265.00 USD
3/18/2026265.00 USD
3/17/2026269.48 USD
3/16/2026261.24 USD
3/13/2026262.80 USD
3/12/2026261.82 USD
3/11/2026269.89 USD
3/10/2026267.85 USD
3/9/2026271.44 USD
3/6/2026269.85 USD
3/5/2026279.03 USD
3/4/2026284.68 USD
3/3/2026280.19 USD
3/2/2026279.59 USD
2/27/2026278.44 USD
2/26/2026275.21 USD
2/25/2026269.65 USD
2/24/2026268.70 USD
2/23/2026268.25 USD
2/20/2026271.30 USD
2/19/2026271.90 USD
2/18/2026270.67 USD
2/17/2026264.93 USD
2/13/2026256.56 USD
2/12/2026256.56 USD
2/11/2026292.42 USD
2/10/2026293.69 USD
2/9/2026299.96 USD
2/8/2026294.90 USD
2/6/2026301.50 USD
2/5/2026301.50 USD
2/4/2026299.54 USD
2/3/2026305.90 USD
2/2/2026298.98 USD
2/1/2026297.43 USD
1/30/2026293.70 USD
1/29/2026293.70 USD
1/28/2026294.91 USD
1/27/2026299.79 USD
1/26/2026297.71 USD
1/25/2026299.28 USD
1/23/2026296.57 USD
1/22/2026296.57 USD
1/21/2026305.22 USD
1/20/2026311.54 USD
1/19/2026312.76 USD
1/16/2026313.53 USD
1/15/2026313.53 USD
1/14/2026322.06 USD
1/13/2026318.25 USD
1/12/2026322.17 USD
1/11/2026323.00 USD
1/9/2026323.82 USD
1/8/2026323.82 USD
1/7/2026319.08 USD
1/6/2026324.09 USD
1/5/2026325.50 USD
1/4/2026322.34 USD
1/2/2026305.27 USD
1/1/2026305.27 USD
12/31/2025302.99 USD
12/30/2025302.99 USD
12/29/2025304.51 USD
12/28/2025303.73 USD
12/26/2025303.88 USD
12/25/2025303.88 USD
12/24/2025301.75 USD
12/23/2025301.75 USD
12/22/2025301.03 USD
12/21/2025304.85 USD
12/19/2025301.53 USD
12/18/2025301.53 USD
12/17/2025299.86 USD
12/16/2025301.28 USD
12/15/2025302.02 USD
12/14/2025307.92 USD
12/12/2025308.13 USD
12/11/2025308.13 USD
12/10/2025313.97 USD
12/9/2025315.00 USD
12/8/2025308.05 USD
12/7/2025308.53 USD
12/5/2025317.69 USD
12/4/2025317.69 USD
12/3/2025320.06 USD
12/2/2025320.34 USD
12/1/2025318.56 USD
11/30/2025321.50 USD
11/28/2025324.86 USD
11/27/2025324.86 USD
11/26/2025327.03 USD
11/25/2025327.03 USD
11/24/2025332.21 USD
11/23/2025322.48 USD
11/21/2025316.70 USD
11/20/2025316.70 USD
11/19/2025303.61 USD
11/18/2025304.79 USD
11/17/2025307.78 USD
11/16/2025304.06 USD
11/14/2025313.15 USD
11/13/2025313.15 USD
11/12/2025316.89 USD
11/11/2025327.28 USD
11/10/2025313.33 USD
11/9/2025307.38 USD
11/7/2025305.56 USD
11/6/2025305.56 USD
11/5/2025306.55 USD
11/4/2025310.01 USD
11/3/2025310.96 USD
11/2/2025311.43 USD
10/31/2025319.55 USD
10/30/2025319.55 USD
10/29/2025304.61 USD
10/28/2025319.47 USD
10/27/2025330.42 USD
10/26/2025336.12 USD
10/24/2025339.75 USD
10/23/2025339.75 USD
10/22/2025338.67 USD
10/21/2025333.97 USD
10/20/2025331.27 USD
10/19/2025321.90 USD
10/17/2025313.02 USD
10/16/2025310.02 USD
10/15/2025312.39 USD
10/14/2025305.85 USD
10/13/2025305.05 USD
10/12/2025303.71 USD
10/10/2025297.72 USD
10/9/2025297.72 USD
10/8/2025300.63 USD
10/7/2025302.83 USD
10/6/2025296.52 USD
10/5/2025309.17 USD
10/3/2025305.54 USD
10/2/2025305.49 USD
10/1/2025294.24 USD
9/30/2025297.95 USD
9/29/2025280.39 USD
9/28/2025270.11 USD
9/25/2025271.36 USD
9/24/2025270.41 USD
9/23/2025276.62 USD
9/22/2025282.07 USD
9/21/2025283.36 USD
9/19/2025284.09 USD
9/18/2025284.07 USD
9/17/2025286.49 USD
9/16/2025280.29 USD
9/15/2025282.26 USD
9/14/2025280.21 USD
9/12/2025280.36 USD
9/11/2025280.34 USD
9/10/2025285.90 USD
9/9/2025276.91 USD
9/8/2025285.95 USD
9/7/2025290.38 USD
9/5/2025295.45 USD
9/4/2025295.43 USD
9/3/2025289.43 USD
9/2/2025288.05 USD
9/1/2025290.71 USD
8/29/2025297.90 USD
8/28/2025297.88 USD
8/27/2025293.67 USD
8/26/2025292.84 USD
8/25/2025296.60 USD
8/24/2025297.37 USD
8/22/2025307.69 USD
8/21/2025303.82 USD
8/20/2025285.03 USD
8/19/2025288.16 USD
8/18/2025288.37 USD
8/17/2025284.65 USD
8/15/2025285.70 USD
8/14/2025285.66 USD
8/13/2025287.21 USD
8/12/2025287.16 USD
8/11/2025274.76 USD
8/10/2025264.53 USD
8/8/2025264.23 USD
8/7/2025264.21 USD
8/6/2025265.26 USD
8/5/2025264.32 USD
8/4/2025272.18 USD
8/3/2025276.80 USD
7/31/2025284.60 USD
7/30/2025241.95 USD
7/29/2025250.08 USD
7/28/2025252.60 USD
7/27/2025253.23 USD
7/25/2025264.08 USD
Access this data via the Eulerpool API
Get Free API Key

Bio Rad Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
2.55 B USD
443.19 M USD
3.81 B USD
Jan 1, 2021
2.92 B USD
501.89 M USD
4.25 B USD
Jan 1, 2022
2.80 B USD
482.62 M USD
-3.63 B USD
Jan 1, 2023
2.67 B USD
337.80 M USD
-637.32 M USD
Jan 1, 2024
2.57 B USD
269.00 M USD
-1.84 B USD
Jan 1, 2025
2.58 B USD
270.50 M USD
759.90 M USD
Jan 1, 2026 (e)
2.57 B USD
334.19 M USD
253.99 M USD
Jan 1, 2027 (e)
2.63 B USD
367.64 M USD
274.29 M USD

Bio Rad Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 25, 2026, 4:33 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
2.072.132.182.022.072.162.292.312.552.922.802.672.572.582.572.63
-0.193.042.02-7.172.434.456.020.9210.1314.81-4.11-4.68-3.930.66-0.622.61
56.1155.2554.1655.5255.0354.9553.4554.3956.4656.0655.9253.3953.7051.9951.9951.99
1.161.181.181.121.141.191.221.261.441.641.571.431.381.341.331.37
264.00169.00149.00166.0053.00115.00-108.00229.00443.00501.00482.00337.00269.00270.00334.00367.00
12.767.936.858.222.565.32-4.729.9117.4117.1517.2012.6210.4810.4513.0113.93
0.170.080.090.110.030.110.361.763.814.25-3.63-0.64-1.840.760.250.27
-5.06-54.4414.2928.41-75.22307.14215.79388.33116.9511.54-185.26-82.44189.48-141.16-66.678.30
28.7128.9929.1929.4729.5530.1129.8830.2230.1729.9229.7928.8228.0027.0127.0127.01
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Bio Rad Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bio Rad Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bio Rad Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Bio Rad Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bio Rad Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Bio Rad Laboratories stock margins

The Bio Rad Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio Rad Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio Rad Laboratories.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
56.48 %
17.41 %
149.83 %
Jan 1, 2021
56.05 %
17.17 %
145.57 %
Jan 1, 2022
55.93 %
17.22 %
-129.45 %
Jan 1, 2023
53.42 %
12.65 %
-23.86 %
Jan 1, 2024
53.73 %
10.48 %
-71.86 %
Jan 1, 2025
52.01 %
10.47 %
29.42 %
Jan 1, 2026 (e)
52.01 %
13.02 %
9.89 %
Jan 1, 2027 (e)
52.01 %
13.95 %
10.41 %

Bio Rad Laboratories Stock Revenue, EBIT, Earnings per Share

The Bio Rad Laboratories earnings per share therefore indicates how much revenue Bio Rad Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
84.38 USD
14.69 USD
126.42 USD
Jan 1, 2021
97.67 USD
16.77 USD
142.18 USD
Jan 1, 2022
94.06 USD
16.20 USD
-121.76 USD
Jan 1, 2023
92.70 USD
11.72 USD
-22.12 USD
Jan 1, 2024
91.67 USD
9.61 USD
-65.87 USD
Jan 1, 2025
95.63 USD
10.01 USD
28.13 USD
Jan 1, 2026 (e)
90.99 USD
12.37 USD
9.00 USD
Jan 1, 2027 (e)
93.39 USD
13.61 USD
9.72 USD

Bio Rad Laboratories business model & stock analysis

Bio-Rad Laboratories Inc. is a leading company in the field of scientific research based in Hercules, California. The company was founded in 1952 by two brothers and has since developed into a multinational company with over 8,000 employees worldwide. Bio-Rad has branches in over 100 countries and its products are used in biotechnology, pharmaceuticals, and the food industry. History Bio-Rad was founded in 1952 by the couple David and Alice Schwartz. They started with the production of blood group serology tests and later expanded their product range to include immunchemicals, electrophoresis equipment, and antibodies. In the 1970s, Bio-Rad developed the first commercial protein A purification system, which is still an important component of protein research today. Business model Bio-Rad's business model is focused on providing high-quality products and services to support customers in their scientific research. The company has various divisions such as life science research, clinical diagnostics, and life science education, which offer products and solutions for scientists, researchers, and diagnosticians. Life science research The life science research division offers a wide range of products and services for biological research. This includes PCR systems, electrophoresis equipment, antibodies, proteins, cell counters, and much more. Bio-Rad's products are used by scientists and researchers around the world to better understand the intricacies of life and the mechanisms of diseases. Clinical diagnostics Bio-Rad's clinical diagnostics division provides a broad spectrum of diagnostic products and solutions for hospitals, laboratories, and medical facilities. The company provides clinical diagnostic instruments, reagents, testing systems, and software to support the diagnostic process. Life science education The life science education division offers innovative and interactive teaching and learning materials for scientific research to teachers, professors, and students. Bio-Rad's products and solutions support the better understanding of the intricacies of life and the mechanisms of diseases in the fields of biology, chemistry, and physics. Products Bio-Rad offers a wide range of products and solutions for research and diagnostics. These include, among others: PCR systems: Bio-Rad offers various PCR systems that help researchers and diagnosticians amplify and analyze DNA. The systems are highly precise and provide reliable results. Proteins and antibodies: Bio-Rad offers a wide selection of proteins and antibodies for research and diagnostics. The products include various types of proteins and antibodies needed for the analysis of protein functions and interactions. Electrophoresis equipment: Bio-Rad provides various electrophoresis equipment that plays an important role in research and diagnostics. The products include gel electrophoresis systems, Western blot systems, and devices for protein analysis. Clinical diagnostics: Bio-Rad offers a wide range of diagnostic products for hospitals, laboratories, and medical facilities. These include immunoassay products, blood group serology tests, and devices for the diagnosis of infectious diseases. In summary, Bio-Rad Laboratories Inc. is a leading company in the field of scientific research. The company offers a wide range of products and solutions for research and diagnostics, supporting scientists, researchers, and diagnosticians around the world in exploring the intricacies of life and better understanding diseases.

Bio Rad Laboratories SWOT Analysis

Strengths

Bio Rad Laboratories Inc is a leading global provider of life science research and clinical diagnostics products. The company has an extensive product portfolio, ranging from instruments and reagents to software and services, catering to the needs of various scientific and healthcare professionals.

Bio Rad has a strong brand reputation and is recognized for its high-quality and innovative solutions. This reputation enables the company to attract and retain loyal customers in the highly competitive life sciences industry.

The company's research and development capabilities are a significant strength, as they allow Bio Rad to constantly introduce new products and technologies to meet changing market demands.

Weaknesses

Despite its strong market position, Bio Rad faces certain weaknesses. One of these weaknesses is its dependence on a limited number of key customers, which puts the company at risk if any of these customers reduce their purchasing volumes or switch to competitors.

Another weakness is the company's limited geographic diversification. Bio Rad operates primarily in the United States, making it vulnerable to fluctuations in the domestic market and potentially missing out on international growth opportunities.

Opportunities

Bio Rad has several opportunities for growth. The increasing global focus on healthcare and research presents opportunities for the company to expand its customer base and enhance market penetration. The growing demand for personalized medicine and genetic testing also offers new avenues for product development and revenue generation.

Furthermore, strategic partnerships and collaborations with other industry players or academic institutions can provide Bio Rad with access to complementary technologies and expertise, enabling the company to offer more comprehensive solutions to its customers.

Threats

The highly competitive nature of the life sciences industry poses a significant threat to Bio Rad. The company faces intense competition from both large multinational corporations and smaller specialized companies, which may have competitive advantages in certain niche markets.

Additionally, regulatory requirements and compliance challenges in the healthcare and life sciences sectors can pose risks and add complexity to Bio Rad's operations. Changes in regulations or failure to comply with existing ones may impact the company's ability to market and sell its products.

Bio Rad Laboratories Segments

Bio Rad Laboratories Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • Max

Clinical Diagnostics
Life Science
Details
Date
Clinical Diagnostics
Life Science
Jan 1, 2019
1.41 B USD
0.00 USD
Jan 1, 2020
1.31 B USD
1.23 B USD
Jan 1, 2021
1.52 B USD
1.40 B USD
Jan 1, 2022
1.45 B USD
1.35 B USD
Jan 1, 2023
1.49 B USD
1.18 B USD

Bio Rad Laboratories Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • Max

All Other Segments
Details
Date
All Other Segments
Jan 1, 2019
0.00 USD
Jan 1, 2020
8.60 M USD
Jan 1, 2021
5.80 M USD
Jan 1, 2022
4.00 M USD
Jan 1, 2023
3.60 M USD

Bio Rad Laboratories Revenue by Segment (3/3)

  • 3 Years

  • 5 Years

  • Max

Life Science
All Other Segments
Details
Date
Life Science
All Other Segments
Jan 1, 2019
885.90 M USD
13.80 M USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD

Bio Rad Laboratories Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Europe
Asia
Other (primarily Canada and Latin America)
Details
Date
United States
Europe
Asia
Other (primarily Canada and Latin America)
Jan 1, 2019
899.10 M USD
770.30 M USD
505.00 M USD
137.30 M USD
Jan 1, 2020
1.00 B USD
857.70 M USD
546.50 M USD
136.60 M USD
Jan 1, 2021
1.13 B USD
946.90 M USD
688.40 M USD
156.60 M USD
Jan 1, 2022
1.16 B USD
851.90 M USD
639.40 M USD
155.40 M USD
Jan 1, 2023
1.12 B USD
819.80 M USD
563.00 M USD
166.60 M USD
Jan 1, 2024
1.04 B USD
834.10 M USD
521.60 M USD
169.30 M USD
Jan 1, 2025
1.02 B USD
881.80 M USD
513.30 M USD
165.40 M USD

Bio Rad Laboratories Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Bio Rad Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

Bio Rad Laboratories annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Bio Rad Laboratories shares outstanding

The number of shares of Bio Rad Laboratories was 27.01 M in 2025. This indicates how many shares Bio Rad Laboratories is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
30.17 M Stocks
Jan 1, 2021
29.92 M Stocks
Jan 1, 2022
29.79 M Stocks
Jan 1, 2023
28.82 M Stocks
Jan 1, 2024
28.00 M Stocks
Jan 1, 2025
27.01 M Stocks
Jan 1, 2026 (e)
27.01 M Stocks
Jan 1, 2027 (e)
27.01 M Stocks

Current Bio Rad Laboratories forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy60.00 % (6)
Hold40.00 % (4)
Sell0.00 % (0)
12M Price Target
372.30
Last Price
316.38
Currency
USD
12M Return Potential
17.67 %
LTM Return
0 %

Bio Rad Laboratories Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
7/30/20261.77USD630.23 MUSD2026 Q2
4/30/20262.00USD594.76 MUSD2026 Q1
2/12/20262.74USD700.89 MUSD2025 Q4
2/11/20262.74USD700.89 MUSD2025 Q4
5/2/20243.35USD673.76 MUSD2024 Q1
2/14/20242.89USD692.41 MUSD2023 Q4
7/28/20222.83USD692.86 MUSD2022 Q2
8/7/20181.28USD556.66 MUSD2018 Q2

EESG©

Eulerpool ESG Scorecard© for the Bio Rad Laboratories stock

41/100
41
Environment
62
Social
20
Governance
E

Environment

20
Scope 1 - Direct Emissions10,563
Scope 2 - Indirect emissions from purchased energy13,906
Scope 3 - Indirect emissions within the value chain295,930
Total CO₂ emissions24,469
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees44
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Bio Rad Laboratories shareholder structure

% Name
8.92221%
First Eagle Investment Management, L.L.C.
First Eagle Investment Management, L.L.C.
6.52908%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
6.31373%
Alice N. Schwartz Revocable Trust
Alice N. Schwartz Revocable Trust
5.47543%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.94134%
Schwartz (Norman D)
Schwartz (Norman D)
3.54281%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

Bio Rad Laboratories Executives and Management Board

NS

Mr. Norman Schwartz

(75)

Chairman of the Board, Chief Executive Officer · since 1995

Compensation8.29 M USD
JD

Mr. Jonathan Divincenzo

(59)

President, Chief Operating Officer

Compensation4.31 M USD
RL

Mr. Roop Lakkaraju

(54)

Chief Financial Officer, Executive Vice President

Compensation3.78 M USD
MC

Mr. Michael Crowley

(63)

Executive Vice President - Global Commercial Operations

Compensation2.24 M USD
EE

Ms. Eva Anette Engelhardt

(55)

Executive Vice President, President of Clinical Diagnostics Group

Compensation2.23 M USD

Bio Rad Laboratories Supply Chain

Bio Rad Laboratories Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
14 companies
#Name1M3M6M1Y2YTrend
1
Sartorius Vz
Supplier
0.51
0.86
0.96
0.96
0.94
2
Danaher Corporation
0.85
0.92
0.92
0.90
0.87
3
Biotest Vz I
Supplier
0.14
-0.26
0.83
0.40
0.68
#Name1M3M6M1Y2YTrend
1
Quantum-Si A
Supplier
0.58
0.61
0.84
0.64
—
2
Seegene, Inc.
0.54
0.58
0.82
0.54
—
3
Luminex Corporation
Supplier
0.46
-0.25
-0.89
-0.90
—
4
DCC plc
-0.43
—
—
—
—
5
Biodesix
Supplier
-0.25
0.36
0.85
0.59
—

Frequently asked questions about Bio Rad Laboratories

The business model of Bio Rad Laboratories Inc. revolves around refining and providing innovative solutions for the life science research and diagnostic markets. As a leading global provider of products and systems, Bio Rad Laboratories Inc. focuses on developing and manufacturing a wide range of specialized products. These include instruments, reagents, consumables, software, and services that cater to medical diagnostics, scientific research, and biopharmaceutical production. By continuously investing in research and development, Bio Rad Laboratories Inc. aims to meet the diverse needs of its customers, drive scientific advancements, and improve patient outcomes worldwide.

All fundamentals and in-depth analysis of Bio Rad Laboratories

Our stock analysis for Bio Rad Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio Rad Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Bio Rad Laboratories Stock
Bio Rad Laboratories Revenue→
Bio Rad Laboratories Stock
Bio Rad Laboratories Net Income→
Bio Rad Laboratories Stock
Bio Rad Laboratories P/E→
Bio Rad Laboratories Stock
Bio Rad Laboratories P/S→
Bio Rad Laboratories Stock
Bio Rad Laboratories EBIT→
Bio Rad Laboratories Stock
Bio Rad Laboratories Dividend→
Bio Rad Laboratories Stock
Bio Rad Laboratories Directors Dealings→
Bio Rad Laboratories Stock
Bio Rad Laboratories Stocks→
Bio Rad Laboratories Stock
Bio Rad Laboratories Market capitalization→
Bio Rad Laboratories Stock
Bio Rad Laboratories Debt→
Bio Rad Laboratories Stock
Bio Rad Laboratories Liabilities→
Bio Rad Laboratories Stock
Bio Rad Laboratories Equity→
Bio Rad Laboratories Stock
Bio Rad Laboratories AAQS→
Bio Rad Laboratories Stock
Bio Rad Laboratories Employees→
Bio Rad Laboratories Stock
Bio Rad Laboratories ROE→
Bio Rad Laboratories Stock
Bio Rad Laboratories ROA→
Bio Rad Laboratories Stock
Bio Rad Laboratories ROCE→
Bio Rad Laboratories Stock
Bio Rad Laboratories News→
Bio Rad Laboratories Stock
Bio Rad Laboratories Analyst Price Targets→

Health Stocks

Bio Solution CoBio Preventive MedicineBio ViewBio Plus CoBio-FD&C CoBio Path HoldingsBio-TechneBio Green Med SolutionBio-Thera SolutionsBinex CoBio-Works TechnologiesBimergen EnergyAll Stocks A–Z →